ankrd52 Antibody

What is ANKRD52 and why is it a significant research target?

ANKRD52 (Ankyrin Repeat Domain 52), also known as PP6-ARS-C, is a 1,076 amino acid phosphoprotein characterized by twenty-eight ankyrin repeats that functions as a regulatory subunit of protein phosphatase 6 (PP6) holoenzyme . This protein plays crucial roles in cell cycle regulation and DNA damage response, contributing to cellular homeostasis maintenance . ANKRD52 has gained research significance due to emerging evidence suggesting its involvement in tumor metastases and cancer cell escape from T cell-mediated elimination and immunotherapy . The gene encoding ANKRD52 is located on human chromosome 12q13.2 and is evolutionarily conserved across multiple species (including chimpanzees, dogs, mice, rats, and zebrafish), indicating fundamental biological importance .

Which applications are most reliable for ANKRD52 antibody detection?

Multiple validated applications exist for ANKRD52 antibody detection, with reliability varying by antibody type and experimental context:

For multiparameter experiments, combining WB for protein size verification with either IHC or IF for localization studies provides the most comprehensive characterization of ANKRD52 expression patterns .

How should antibody validation be performed for ANKRD52 research?

Proper validation of ANKRD52 antibodies should follow a multi-step process:

• Specificity testing: Employ knockout/knockdown controls where ANKRD52 expression is eliminated or reduced. Comparison with wild-type samples should demonstrate corresponding elimination or reduction of antibody signal .

• Cross-reactivity assessment: Test the antibody against human, mouse, and rat samples if working with these models, as ANKRD52 shows conservation across species but with potential epitope variations .

• Application-specific validation: For WB, verify detection of the expected 115 kDa band. For IHC, compare staining patterns against established literature references and include appropriate negative controls .

• Epitope mapping verification: Confirm that the antibody recognizes the intended epitope region. For example, antibodies targeting the AA 433-461 region may have different specificity profiles than those targeting the AA 450-660 region .

• Reproducibility testing: Perform replicate experiments across different sample preparations to ensure consistent results before proceeding with experimental applications .

How should researchers design experiments to investigate ANKRD52's role in cancer progression?

When investigating ANKRD52's role in cancer progression, implement a comprehensive experimental design strategy:

• Expression profiling: Quantify ANKRD52 expression across cancer types and stages using validated antibodies. Recent research shows ANKRD52 expression is elevated in 24 tumor types compared to normal tissues, with particularly strong associations in kidney chromophobe (KICH) .

• Correlation with clinical outcomes: Analyze ANKRD52 expression in relation to patient survival data. Evidence indicates association with poor prognosis, especially in kidney chromophobe cancer, while showing decreased expression in advanced stages of several cancers .

• Functional studies design:

  • Implement ANKRD52 knockdown/overexpression in relevant cell lines

  • Assess effects on proliferation, migration, invasion, and apoptosis

  • Examine downstream signaling pathways altered by ANKRD52 modulation

  • Investigate interactions with PP6 complex components

• Immune interaction assessment: Analyze correlations between ANKRD52 expression and tumor microenvironment features using multiparameter flow cytometry or immunohistochemistry. This is particularly important given ANKRD52's association with immune cell infiltration, ESTIMATE scores, and tumor microenvironment signatures .

• Therapeutic response monitoring: Design experiments to assess how ANKRD52 expression affects sensitivity to anticancer drugs, as research indicates significant correlations between ANKRD52 levels and drug responsiveness .

What are the critical considerations when analyzing ANKRD52 in the tumor microenvironment?

Analysis of ANKRD52 in the tumor microenvironment requires attention to several critical factors:

How can researchers effectively distinguish between ANKRD52's phosphatase regulatory functions and its potential immune regulatory roles?

Separating ANKRD52's distinct functional roles requires sophisticated experimental approaches:

• Domain-specific mutation analysis: Design experiments using constructs with mutations in:

  • Ankyrin repeat domains (affecting protein-protein interactions)

  • Phosphatase binding regions (affecting PP6 regulation)

  • Other functional domains

• Interactome characterization: Implement immunoprecipitation followed by mass spectrometry to identify ANKRD52 binding partners in different cellular contexts. Compare interactomes between:

  • Normal vs. cancer cells

  • Immune-responsive vs. immune-resistant tumors

  • Different tissue and cancer types

• Kinetic analysis protocols: Design pulse-chase experiments to track ANKRD52 activity timing in relation to phosphatase activation and immune signaling events.

• Subcellular localization studies: Use fractionation protocols followed by western blotting or high-resolution microscopy with ANKRD52 antibodies to determine compartment-specific functions .

• Pathway inhibition experiments: Design studies using specific inhibitors of:

  • Phosphatase pathways

  • Immune signaling cascades

  • Cell cycle regulatory mechanisms

  This helps isolate which ANKRD52 functions persist when specific pathways are blocked.

What are the most common causes of inconsistent ANKRD52 antibody performance and their solutions?

Researchers frequently encounter several issues with ANKRD52 antibody applications that can be systematically addressed:

• Inconsistent western blot results:

  • Problem: Multiple or unexpected bands

  • Solution: Use freshly prepared lysates with phosphatase inhibitors (ANKRD52 is a phosphoprotein); optimize antibody concentration to 1:1000 for polyclonal antibodies; employ longer blocking times (2 hours minimum)

• Poor signal in immunohistochemistry:

  • Problem: Weak or absent staining

  • Solution: Implement microwave antigen retrieval with 10 mM PBS buffer pH 7.2; extend primary antibody incubation to overnight at 4°C; use amplification systems for low-expressing samples

• Batch-to-batch antibody variability:

  • Problem: Performance differences between antibody lots

  • Solution: Validate each new lot against a reference sample; maintain consistent positive controls across experiments; consider monoclonal antibodies for critical applications

• Fixation artifacts:

  • Problem: False negative results in fixed tissues

  • Solution: Compare multiple fixation protocols; limit fixation time to preserve epitope accessibility; validate with multiple detection methods

• Cross-reactivity issues:

  • Problem: Non-specific binding in multi-species studies

  • Solution: Select antibodies validated for specific species; perform pre-adsorption controls; confirm specificity with genetic knockdown models

How should contradictory ANKRD52 expression data between different detection methods be reconciled?

When faced with contradictory ANKRD52 expression data across methods, implement this systematic reconciliation approach:

• Method hierarchy establishment: Prioritize data based on method reliability:

  • Quantitative PCR for transcript levels

  • Western blotting with validated antibodies for protein levels

  • Immunohistochemistry for spatial distribution

  • Consider each as measuring different aspects rather than competing results

• Epitope accessibility analysis: Different antibodies target distinct regions of ANKRD52 (e.g., AA 433-461 vs. AA 450-660) ; protein conformation or interactions may mask certain epitopes in specific applications.

• Sample preparation comparison: Systematically compare:

  • Fresh vs. frozen vs. fixed tissues

  • Different lysis buffers for protein extraction

  • Various fixation protocols

  • Multiple antibody clones

• Isoform-specific analysis: Design experiments to distinguish potential ANKRD52 isoforms using:

  • Isoform-specific primers for PCR

  • Antibodies targeting unique regions

  • Size-based separation methods

• Technical vs. biological variance assessment: Implement statistical approaches to distinguish:

  • Technical variability (replicates with same sample)

  • Biological variability (different samples)

  • Systematic error (consistent bias in one method)

What are the optimal protocols for co-immunoprecipitation studies involving ANKRD52 and the PP6 complex?

For successful co-immunoprecipitation of ANKRD52 with PP6 complex components, follow these optimized protocols:

• Lysis buffer optimization:

  • Use gentle, non-denaturing buffer containing:

    • 50 mM Tris-HCl (pH 7.5)

    • 150 mM NaCl

    • 0.5% NP-40 or 1% Triton X-100

    • 1 mM EDTA

    • Phosphatase inhibitor cocktail (critical for maintaining complex integrity)

    • Protease inhibitor cocktail

• Antibody selection strategy:

  • For ANKRD52 pull-down: Mouse monoclonal ANKRD52 antibody (A-1) shows superior performance

  • For reverse co-IP: Use antibodies against PP6 catalytic or other regulatory subunits

  • Pre-clear lysates with appropriate control IgG

  • Cross-validate results with reciprocal co-IPs

• Complex preservation techniques:

  • Maintain samples at 4°C throughout processing

  • Avoid freeze-thaw cycles of lysates

  • Consider mild crosslinking (0.1-0.5% formaldehyde) to stabilize transient interactions

  • Use shorter washing steps to preserve weaker interactions

• Detection optimization:

  • For western blot detection after IP:

    • Use rabbit polyclonal antibodies when mouse antibodies were used for IP

    • Implement clean detection systems (avoid heavy chain interference)

    • Consider specialized secondary antibodies that don't recognize denatured IgG

• Controls and validation:

  • Input control (5-10% of lysate)

  • IgG control (matched isotype)

  • Positive control (known interactor)

  • Negative control (non-interacting protein)

  • Validate interactions with alternative methods (proximity ligation assay, etc.)

How can ANKRD52 antibodies be applied in cancer immunotherapy research?

ANKRD52 antibodies offer valuable applications in cancer immunotherapy research based on recent findings connecting ANKRD52 to immune responses:

• Predictive biomarker development:

  • Use validated ANKRD52 antibodies for immunohistochemical screening of patient samples

  • Correlate expression patterns with immunotherapy response

  • Develop quantitative scoring systems based on staining intensity and distribution

  • Generate multiplexed panels including ANKRD52 alongside established markers

• Mechanism investigation protocols:

  • Design experiments examining how ANKRD52 modulates:

    • Tumor-infiltrating lymphocyte activity

    • Checkpoint molecule expression

    • Antigen presentation pathways

    • Cytokine signaling networks

• Therapeutic resistance studies:

  • Monitor ANKRD52 expression changes before and after immunotherapy

  • Correlate expression with tumor mutational burden (TMB) and microsatellite instability (MSI), as ANKRD52 shows significant associations with these immunotherapy response predictors in multiple cancer types

  • Analyze post-treatment samples from responding vs. non-responding patients

• Combination therapy optimization:

  • Assess how ANKRD52 levels predict response to combined targeted and immunotherapies

  • Investigate potential for ANKRD52-targeting approaches to enhance immunotherapy efficacy

  • Develop experimental models with modulated ANKRD52 expression to test therapeutic combinations

• Diagnostic application development:

  • Create standardized ANKRD52 immunohistochemistry protocols for clinical testing

  • Establish expression thresholds correlated with treatment outcomes

  • Validate in multi-institutional cohorts

What are the methodological considerations for studying ANKRD52 in relation to tumor mutational burden and microsatellite instability?

Investigating relationships between ANKRD52, tumor mutational burden (TMB), and microsatellite instability (MSI) requires specific methodological approaches:

What novel applications of ANKRD52 antibodies are emerging in single-cell analysis and spatial transcriptomics?

Emerging applications of ANKRD52 antibodies in advanced analytical platforms include:

• Single-cell protein profiling protocols:

  • Optimization of ANKRD52 antibodies for mass cytometry (CyTOF)

  • Development of antibody panels including ANKRD52 for high-dimensional analysis

  • Integration with phospho-protein markers to track PP6 pathway activity

  • Correlation with immune cell phenotypes at single-cell resolution

• Spatial biology integration approaches:

  • Adaptation of validated antibodies for multiplexed immunofluorescence platforms

  • Optimization protocols for ANKRD52 detection in spatial transcriptomics

  • Co-detection with PP6 complex components to map functional interactions

  • Neighborhood analysis to identify ANKRD52-associated microenvironmental features

• Multi-omic single-cell analysis strategies:

  • CITE-seq adaptation using ANKRD52 antibodies for simultaneous protein and RNA detection

  • Single-cell western blotting for heterogeneity assessment

  • Proximity ligation assays at single-cell resolution

  • Correlation of protein levels with transcriptional signatures

• Dynamic protein behavior investigation:

  • Live-cell imaging using fluorescently tagged ANKRD52 antibody fragments

  • Pulse-chase studies at single-cell resolution

  • Visualization of protein translocation in response to stimuli

  • Quantification of protein half-life and turnover rates

• Clinical application development:

  • Minimal residual disease detection using high-sensitivity ANKRD52 detection

  • Circulating tumor cell characterization

  • Extracellular vesicle cargo analysis

  • Predictive biomarker development for precision oncology applications

How does ANKRD52 expression correlate with prognosis across different cancer types, and what methods provide the most reliable assessment?

Research indicates complex relationships between ANKRD52 expression and cancer prognosis that demand sophisticated assessment:

• Cancer-specific prognostic patterns:

  • Poor prognosis association: Highest in kidney chromophobe (KICH)

  • Expression level dynamics: Generally higher in 24 tumor types versus normal tissues, but lower in advanced cancer stages

  • Methodological reliability hierarchy:

    • Multivariate survival analysis controlling for clinical variables

    • IHC on tissue microarrays with standardized scoring

    • Combined transcript and protein measurement

    • Meta-analysis across independent cohorts

• Quantification standardization parameters:

  • For IHC assessment:

    • H-score (intensity × percentage) provides more nuanced evaluation than binary positive/negative

    • Digital pathology quantification reduces inter-observer variability

    • Internal controls on each slide ensure technical consistency

  • For transcript analysis:

    • Normalization to multiple reference genes improves reliability

    • Cancer-specific reference genes may be required

• Heterogeneity assessment approaches:

  • Spatial heterogeneity: Multiple sampling regions per tumor

  • Temporal heterogeneity: Longitudinal sampling when possible

  • Molecular context: Assessment alongside known prognostic markers

• Survival analysis methodology:

  • Kaplan-Meier with log-rank testing for initial assessment

  • Cox proportional hazards for multivariate analysis

  • Competing risk models for comprehensive evaluation

  • Landmark analysis to account for time-dependent effects

• Clinical implementation considerations:

  • Standardized reporting guidelines development

  • Clinically applicable cutoff determination

  • Integration with existing prognostic tools

  • Prospective validation requirements

What experimental designs best elucidate the dual role of ANKRD52 in phosphatase regulation and immune modulation?

Investigating ANKRD52's dual functionality requires sophisticated experimental designs:

• Domain-specific functional mapping:

  • Generate constructs with mutations in:

    • Ankyrin repeat domains (protein interaction)

    • PP6 binding regions

    • Potential immune regulatory domains

  • Assess each variant's effect on:

    • Phosphatase activity (using phospho-specific antibodies and enzymatic assays)

    • Immune signaling (cytokine production, T cell activation)

    • Protein-protein interactions (co-IP, proximity ligation)

• Cell type-specific function analysis:

  • Compare ANKRD52 interactomes between:

    • Cancer cells vs. immune cells

    • Different immune cell subsets

    • Normal vs. malignant counterparts

  • Utilize CRISPR-based approaches for endogenous protein manipulation

• Phosphoproteome impact assessment:

  • Implement quantitative phosphoproteomics to identify:

    • Substrates affected by ANKRD52 modulation

    • Pathway enrichment following ANKRD52 manipulation

    • Temporal dynamics of phosphorylation changes

  • Validate key targets with phospho-specific antibodies

• Integrated in vivo models:

  • Develop conditional knockout models targeting:

    • Tumor cells specifically

    • Immune cell populations

    • Both compartments

  • Assess tumor growth, immune infiltration, and response to therapy

• Translational correlation studies:

  • Design cohort studies examining relationships between:

    • ANKRD52 expression/mutation status

    • Phosphatase activity markers

    • Immune infiltration patterns

    • Clinical outcomes and therapy response

How can researchers effectively incorporate ANKRD52 antibodies in drug development and therapeutic response monitoring?

ANKRD52 antibodies offer valuable applications in therapeutic development and monitoring:

• Target validation methodologies:

  • Use ANKRD52 antibodies to confirm target engagement by:

    • Assessing protein level changes

    • Detecting altered complex formation

    • Identifying downstream pathway modulation

    • Monitoring subcellular localization shifts

• Pharmacodynamic marker development:

  • Design immunoassays to track ANKRD52-related responses:

    • ELISA-based quantification in accessible samples

    • IHC protocols for biopsy specimens

    • Phospho-specific detection of pathway activity

    • Multiplex approaches integrating multiple readouts

• Patient stratification approaches:

  • Develop standardized ANKRD52 assessment for trial enrollment:

    • IHC scoring systems with clinical cutoffs

    • Correlation with other biomarkers (TMB, MSI)

    • Integration with molecular subtyping

  • Given ANKRD52's links to drug sensitivity, this could enhance precision medicine approaches

• Resistance mechanism investigation:

  • Track changes in ANKRD52 expression/localization during treatment

  • Correlate with emerging resistance

  • Identify compensatory pathway activation

  • Develop combination strategies addressing resistance

• Novel therapeutic target assessment:

  • Evaluate ANKRD52 itself as a potential target using:

    • Protein-protein interaction disruptors

    • Targeted degradation approaches

    • Function-modulating antibodies

    • Gene editing therapies

  • Develop screening approaches to identify modulators of ANKRD52 function